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Background
Nanoparticles made from high-Z materials are promising agents to increase radiosen-
sitivity of cancer cells during the application of radiation therapy. Hainfeld et al. (2004, 
2008) demonstrated therapeutic enhancement with gold nanoparticles (GNP) in a 250 
kVp X-ray beam. The dose-enhancing effect was attributed to the photoelectric effect 
and the increased generation of Auger electrons (Pradhan et al. 2009; Jelveh and Chith-
rani 2011; Dorsey et  al. 2013; Kumar et  al. 2013). Further studies have confirmed the 
dose-enhancing effect of GNP in 6 MV X-ray beams, an energy range that is typically 
used for clinical radiation therapy (Detappe et al. 2013; Berbeco et al. 2011; Cho 2005; 
Jones et al. 2010; Lin et al. 2014; Robar et al. 2002; McMahon et al. 2008; Ngwa et al. 
2014).
However, even though gold nanoparticles may be efficient radiosensitizers, it remains 
difficult to measure their exact concentration within the tumor with current clinically 
available imaging methods. To address this issue, multimodal nanoparticles have been 
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proposed that combine both therapeutic and diagnostic functionality. Mignot et al. 2013 
developed a gadolinium-based nanoparticle, AGuIX, which is a non-toxic magnetic 
resonance contrast agent and sufficiently small (sub-5 nm diameter) to allow for renal 
clearance (Le Duc et al. 2014). With an atomic number of Z = 64, gadolinium is a high-Z 
material and therefore also contributes substantial radiation dose enhancement. (Sancey 
et al. 2014).
Previous assessment of AGuIX nanoparticles has mostly focused on their imaging 
properties (Di Corato et al. 2013; Le Duc et al. 2011; Bianchi et al. 2014a, b; Paul et al. 
2014). In vitro experiments have included different cell lines and preclinical irradiation 
beams (microbeam radiation therapy, low-energy X-ray). Researchers have shown early 
evidence of radiosensitization (Bianchi et al. 2013; Aspord et al. 2013; Mowat et al. 2011; 
Porcel et  al. 2014; Stefančíková et  al. 2014; Luchette et  al. 2014). In addition, in  vivo 
experiments with intravenous or intra-tumoral injection for subcutaneous and ortho-
topic lesions have been performed in preclinical radiation beams (Le Duc et  al. 2011; 
Bianchi et al. 2014a).
The aim of the current study is to characterize the uptake of the AGuIX nanoparti-
cles in pancreatic cancer cells by magnetic resonance imaging (MRI), and investigate the 
radiation dose enhancement effect attributable to AGuIX when irradiating the cells with 
a clinical linear accelerator at 6 MV. This represents the first step towards demonstrat-
ing an in vivo effect for pancreatic cancer. The AGuIX platform is particularly relevant 
for pancreatic cancer due to the poor prognosis, proximity of organs at risk, and target-
ing difficulty for this disease in radiation therapy. AGuIX offers a solution that is highly 
compatible with the current trend in radiation oncology towards MRI-based patient 
simulation and MRI-Linac treatment devices (Raaymakers et al. 2011; Keall et al. 2014). 




Panc1 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM), supple-
mented with 10 % fetal bovine serum (FBS) (Sigma, USA), 1 % Penicillin Streptomycin 
Glutamine (Invitrogen, USA) and were stored in a humidified incubator at 37 °C and 5 % 
CO2.
AGuIX nanoparticles (Nano‑H Inc., France)
The nanoparticles are composed of a polysiloxane shell surrounded by DOTA 
(1,4,7,10-tetra-azacyclododecane-1-glutaric anhydride-4,7,10-triacetic acid) covalently 
bound to the inorganic matrix and Gadolinium (Fig. 1a). The size of each nanoparticle 
was measured by dynamic light scattering (DLS) and is 5 ± 0.1 nm (Fig. 1d) with a mass 
of 10 ± 1 kDa. More detailed information on the production process of the nanoparti-
cles may be found in the references (Detappe et al. 2013).
AGuIX uptake analysis with MRI and ICP‑MS
The concentration of the nanoparticles inside the cells was analyzed with a Bruker Bio-
spin 7T Magnetic Resonance Imaging (MRI) scanner. First, a calibration curve without 
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cells was acquired for various concentrations of nanoparticles in the cell culture solu-
tion. The concentration of AGuIX particles used for the experiment is given in gado-
linium equivalent species and chosen based on published literature (Rima et al. 2013). 
Cells were incubated with 0.5 mM (0.5 mg/L) of AGuIX at 37 °C and 5 % CO2 for 30 min, 
1 h, 3 h, 6 h, 24 h and 48 h. After incubation, the cells were washed and trypsinized to 
remove any excess nanoparticles in the solution before scanning. All MRI scans featured 
a RARE-T1 map imaging-sequence with 2 mm slice thickness, repetition time of 10 ms, 
echo time of 21.4 ms, echo train length of 4, flip angle of 180°, and matrix size 256 × 128 
pixels. Each measurement was performed in triplicate.
Inductively coupled plasma mass spectrometry (ICP-MS) was used to validate the 
MRI results. For this procedure, the cells were dissolved in a radio-immuno precipitation 
RIPA buffer and then suspended in water until analysis. ICP-MS is used to determine 
the exact quantity of Gadolinium. As with the MRI measurements, incubation times 
were 30 min, 1 h, 3 h, 6 h, 24 h and 48 h. Each time point was measured in triplicate.
Localization of AGuIX within Panc1 cells
Transmission electronic microscopy (TEM) was performed to investigate the local 
nanoparticle distribution within the cells. A concentration of 0.5  mM of AGuIX was 
Fig. 1 AGuIX uptake studies. a Schematic representation of the activation induced by the external X-ray 
irradiation on the AGuIX. b TEM images (3000×) depict the active endocytosis uptake of AGuIX into the 
tumor cells. Bar 5 µm. c Magnified TEM image (25000×) shows AGuIX nanoparticles captured by endosomal 
vesicles (black arrow) and carried into the cytoplasm. Bar 1 µm. d Hydrodynamic measurement of the AGuIX 
size. e Panc1 cells were incubated for different time points with 0.5 mM of AGuIX. The concentration in pg/
cell measured by MRI and crosschecked by ICP-MS. The MRI measurement is determined with a calibration 
curve allowing the translation between the concentration in AGuIX and the relaxivity time. For both methods 
of measurement, the uptake plateaus after 30 min
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incubated for 1 h with Panc1 cells, followed by washing out residual nanoparticles and 
staining with 4 % formaldehyde and 1 % glutaraldehyde in 0.1 M Pb for imaging.
Irradiation and setup
We investigated cell response to low-energy and high-energy photon irradiation for a 
dose range of 2–10 Gy. For low-energy experiments, we used a Small Animal Radiation 
Research Platform (SARRP) operated at 220 kVp (0.15  mm Cu filter) and a source to 
cell distance of 35 cm. For high-energy irradiations, we used a clinical linear accelerator 
(TrueBeam, Varian Inc, USA) operated at 6 MV with and without a flattening filter in 
the beam line. Using a flattening filter is the current standard (STD) in radiation therapy 
while the use of flattening filter free beams (FFF) is still relatively novel to clinical appli-
cation. Cells were placed on 5 cm of water equivalent material and another 10 cm on top 
to allow for full scattering and back scattering conditions. The source to cell distance 
was 100 cm, field size 10 × 10 cm2 and dose rate 400 cGy/min for both STD and FFF 
deliveries.
Clonogenic assay
Panc1 cells were incubated in DMEM with 0.5 mM of AGuIX following the specifica-
tions below, and then irradiated. After irradiations, the cells were incubated for another 
4  h; afterwards they were washed with PBS, trypsinized and counted. The cells were 
replated in 10 cm dishes at 300 cells per plate and allowed to grow for 10 days, before 
staining with a 1 % crystal violet and 10 % ethanol dye solution. The platting efficiency 
was 67 ± 7 %. The plates were digitally scanned and automatically counted with software 
developed in our group. Measurements were performed in triplicate.
For the 6 MV irradiations, the cells were incubated 1 h and the medium unwashed. For 
the low-energy photon experiments, 4 different configurations were investigated:
A. Irradiation without any nanoparticles.
B. Cells were not incubated with nanoparticles. Nanoparticles were placed in the media 
just prior the irradiation. We called this configuration +IR/−incubation.
C. Cells were incubated with the nanoparticles and the media was changed just prior 
the irradiation. We called this +IR/+washing.
D. Cells were incubated with the nanoparticles and were irradiated. We called this 
+IR/−washing.
The (B) experiment (+IR/−incubation) is a test of the hypothesis that a dose enhance-
ment effect can be caused by nanoparticles located outside the cell. A positive result 
supports the presence of some long-range effects beyond just photoelectric and Auger 
processes.
Data analysis
We quantified the effect of the nanoparticles utilizing three methods commonly found 
in the literature (Sancey et al. 2014; Jain et al. 2011; Chithrani et al. 2010; Roeske et al. 
2007). The Dose Enhancement Factor (DEF) is the ratio of the area between the survival 
curves with and without nanoparticles. The DEF20 % is the ratio of doses at 20 % survival 
Page 5 of 9Detappe et al. Cancer Nano  (2015) 6:4 
for irradiation without nanoparticles versus with nanoparticles. The sensitivity enhance-
ment ratio at 4 Gy (SER4Gy) is the ratio of survival fractions at 4 Gy for irradiation with-
out and with nanoparticles.
To characterize the radiation response of the Panc1 cells with and without AGuIX, we 
employed the classical linear quadratic model (LQM):
Here, S is the cell survival fraction, D the irradiation dose and α and β are parameters 
representing direct lethal and sub-lethal damage, respectively. Statistical significance of 




Results from both MRI and ICP-MS uptake analyses are shown in Fig. 1. Both methods 
give consistent results and show that AGuIX uptake saturates at about 1.25 pg per cell 
after 30 min incubation time for 0.5 mM of AGuIX incubated.
TEM imaging (Fig. 1b, c) reveals that after 1 h of incubation, the nanoparticles are pre-
dominantly localized in vacuoles in the cytoplasm. This result is in agreement with the 
previously published studies that applied AGuIX to other cell lines (Stefančíková et al. 
2014; Rima et al. 2013).
MRI and ICP-MS results both show a constant level of nanoparticles inside the cells 
after 30 min of incubation. The MRI measurement is systematically larger than the ICP-
MS measurement. This is because the T1 signal is sensitive to the size of nanoparticles, 
which decrease during hydrolysis (which occurs due to the low AGuIX concentration) 
(Le Duc et al. 2014).
Activation of the nanoparticles
For the highest probability of a photoelectric interaction with the K-shell of Gadolinium, 
the incident photon should have an energy just above 50 keV. Figure 2a shows a com-
parison of the low-energy photon spectra for the beams used in this study. Spectra are 
generated using EGSnrc Monte Carlo code (Tsiamas et al. 2011, 2014).
From these distributions, it is clear that 220 kVp is expected to have the highest dose 
enhancement. However, it is not clinically feasible to use low-energy photons to treat 
the majority of patients (especially pancreatic cancer patient) due to the poor penetra-
tion depth and skin-sparing properties. Figure 2b shows a comparison of the percentage 
depth dose (PDD) for the radiation beams used in this study. The best trade-off between 
penetration depth and proportion of low-energy photons exists for the 6 MV FFF beam. 
Further modifications of the 6 MV beam, including the use of a low-Z target, (Parsons 
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Dose enhancement effects
A significant radiosensitization effect was observed for all the clonogenic assays 
performed (Fig.  3). Results of the dose enhancement studies are summarized in 
Table  1. The dose enhancement effect appears to increase with the proportion of 
low-energy photons in the spectrum as expected (Detappe et  al. 2013; Berbeco 
et  al. 2011). For the high-energy (clinical) photon beams, cell killing is significantly 
increased by the removal of the flattening filter in the FFF beam, compared to the 
STD beam (p = 0.014, Wilcoxon). The SER4Gy is 1.20 ± 0.04 for the FFF irradiation 
and 1.12 ± 0.04 for the STD. The DEF20 % is 1.30 ± 0.05 for the FFF and 1.23 ± 0.03 
for the STD.
While the physical property of the incident radiation beams clearly provides a 
therapeutic advantage, there may be other factors contributing as well. Figure 1b, c 
shows the nanoparticles clustered inside the cytoplasm, away from the DNA. Radio-
sensitization was observed for this scenario as well as for non-incubated nanopar-
ticles (located outside the cell) (Fig.  3d). McMahon et  al. (2011) demonstrated the 
role of Auger electrons to create a local effect and the impact of nanoparticle clus-
tering. This local effect increases the formation of reaction oxygen species (ROS), 
such as OH°, H2O2, or HOCl. Some of these ROS have high chemical stabilities and 
a long-range action (few mm) that may increase the cell death even if the nanopar-
ticles are not localized in the cells. The results shown in Fig. 3d are similar to those 
obtained by Porcel et al. (2014) for hadrontherapy. Thus, in addition to the physical 
properties, a biological or chemical effect should be explored to explain the measured 
radiosensitization.
Fig. 2 Representation of the difference between the preclinical beam (SARRP) and the clinical beam. a The 
3 different spectra (220 kVp, 6 MV FFF, and 6 MV STD) were represented near the k-edge of the Gadolinium 
(50.2 kV). Calculation were performed with Monte Carlo simulation at 35 cm source–skin distance; 12 mm 
circular field size for the 220 kVp machine, and at 90 cm source–skin distance; 10 cm depth; 10 × 10 cm2 field 
size for the 6 MV irradiations. b Percentage depth dose (PDD) for the 3 photon beams. The maximum dose for 
the 220 kVp occurs at the surface while it is at approximately 1.5 cm for both 6MV beams
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Conclusion
AGuIX nanoparticles create significant dose enhancement in Panc1 cell lines for low- 
and high-energy photon irradiation. Using a 6 MV flattening filter free (FFF) beam 
improves dose enhancement compared to a standard 6 MV beam. Because of their con-
trast in MRI images, AGuIX have excellent potential as theranostic agents (Lux et  al. 
2011; Kunjachan et al. 2012).
Fig. 3 Radiation dose enhancement studies. Clonogenic assays of Panc1 tumor cells post-AGuIX incubation 
(1 h). a Schematic view of the irradiation setup for the preclinical beam (220 kVp) and b for the clinical beam 
(6 MV). The flattening filter is removed for the FFF irradiations. c Schematic representation of the clonogenic 
assay for the preclinical irradiations. Clinical irradiations were performed with the “washing (-)” situation. Blue 
circles represents the cells. Yellow circles represent the nanoparticles. d Preclinical irradiation setup (SARRP) 
was used to induce radiation enhancement effect in AGuIX using a 220 kVp beam (left) and clinical irradiation 
setup (6 MV beam) was used to treat cells with (STD) and without (FFF) flattening filter (right). Linear quad-
ratic models were fitted to experimental data
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